Vivian Kienzle

Research Assistant

Chappell group

Vivian’s education was purposefully across biochemistry, drug development and clinical trials. Her objective was to enhance research outcomes by providing multiple facets of skills to accelerate research outcomes from bench to bedside. Throughout Vivian’s 20-year career, her research has concentrated on assisting with the generation of new vaccines against medically significant diseases, conducting experiments to test their design, efficacy, and safety, hence contributing towards progressing the purified product towards vaccine delivery.

Chappell Group

Utilising Molecular Clamp technology to research and develop vaccines

Qualifications

Master of Medical Science in Drug Development

Bachelor of Science (Medical Science), Honours in Biochemistry

Publications

Gonzalo J. Martínez, Jennifer Y. Barraclough, Shirley Nakhla, Vivian Kienzle, Stacy Robertson, Ziad Mallat, David S. Celermajer, Sanjay Patel. Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients. Bioscience Reports Jan 17, 2017, 37 (1) BSR20160430; DOI: 10.1042/BSR20160430

Alberto Pinzon-Charry, Tonia Woodberry, Vivian Kienzle, Virginia McPhun, Gabriela Minigo, Daniel A. Lampah, Enny Kenangalem, Christian Engwerda, J. Alejandro López, Nicholas M. Anstey, and Michael F. Good. Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. The Journal of Experimental Medicine July 8, 2013 // JEM vol. 210 no. 8 1635-1646.

Leon E. Hugo, James Monkman, Keyur A. Dave, Leesa F. Wockner, Geoff W. Birrell, Emma L. Norris, Vivian J. Kienzle, Maggy T. Sikulu, Peter A. Ryan, Jeffery J. Gorman, and Brian H. Kay| Proteomic Biomarkers for Ageing the Mosquito Aedes aegypti to Determine Risk of Pathogen Transmission | published 11 Mar 2013 | PLOS ONE 10.1371/journal.pone.0058656

Featured projects	Duration
Rapid Response Vaccine Pipeline	2019–2024